<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002020'>Gastroesophageal reflux disease</z:hpo> is generally a lifelong illness that affects many people </plain></SENT>
<SENT sid="1" pm="."><plain>Erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> can occur in up to 65% of patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> and more seriously, <z:hpo ids='HP_0002043'>esophageal stricture</z:hpo>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, can develop </plain></SENT>
<SENT sid="2" pm="."><plain>The severity of symptoms is not a reliable indicator of the severity of erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and although endoscopy is the preferred method to diagnose and grade erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, its routine use is not practical </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, early initiation of treatment with the most effective agent for treating this disease is a practical and logical strategy </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="49200">Proton pump inhibitor</z:chebi> therapy is preferred for the treatment of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>This review provides a quantitative assessment of the efficacy of <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> (Nexium, AstraZeneca), the most effective agent currently available </plain></SENT>
</text></document>